MedPath

A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy of Lavandula Angustifolia Containing Nasal Spray Medical Device in Preventing Deterioration of COVID-19 in Symptomatic Patients

Not Applicable
Conditions
COVID-19 Infection
Registration Number
NCT04974190
Lead Sponsor
The Grasses of Eden Ltd
Brief Summary

A Nasal Spray device containing Dead Sea minerals and plant extracts, used to shorten duration and mitigate effects of Covid-19 infection in mild to moderate adult patients

Detailed Description

A Nasal Spray device containing Dead Sea minerals and plant extracts, designed to incur a PPAR-alpha agonistic effect, used to shorten duration and mitigate effects of Covid-19 infection in mild to moderate adult patients

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
550
Inclusion Criteria

Having tested positive to Covid-19 on PCR test -

Exclusion Criteria

Pregnancy Low blood pressure On immune system suppressing medications

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Symptoms monitoringFirst 7 days after testing positive on PCR test

Monitoring any disease symptoms reported by patient

Covid-19 infection self-testing on days 2, 4 following testing positive on PCR testFirst 7 days after testing positive on PCR test

Testing using a self testing kit of the Quidel QuickView type

Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.